Brief: FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
14/05/2026 13:37
May 14 (Reuters) - Kyowa Kirin Co Ltd 4151.T: FDA APPROVES NEW DOSING OPTION FOR CRYSVITA® (BUROSUMAB-TWZA) IN ADULTS WITH XLH FDA APPROVES NEW DOSING OPTION FOR CRYSVITA® (BUROSUMAB-TWZA) IN ADULTS WITH XLH KYOWA KIRIN - CRYSVITA DOSE MAY BE INCREASED TO 1 MG/KG EVERY 2 WEEKS AFTER 4 WEEKS Source text: ID:nGNX1NKPXk Further company coverage: 4151.T ((Reuters.Briefs@thomsonreuters.com;))